Literature DB >> 8126833

The use of intravesical oxybutynin chloride in patients with detrusor hypertonicity and detrusor hyperreflexia.

N G Kasabian1, J D Vlachiotis, A Lais, B Klumpp, M D Kelly, M B Siroky, S B Bauer.   

Abstract

Intravesical oxybutynin chloride was administered to 11 children and 7 adults with upper motor neuron bladder dysfunction who were refractory to oral use or who had intolerable side effects from the medication. This therapy was combined with clean intermittent catheterization to ensure complete emptying of the bladder. Five children and 5 adults discontinued therapy due to side effects or the inconvenience of the procedure. The remaining 6 children and 2 adults continue the medication successfully and have shown on followup urodynamic studies that bladder volumes are greater and intravesical pressures are lower than before medication. Intravesical oxybutynin chloride seems to be an effective modality to treat some of these patients but it is not without significant side effects.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8126833     DOI: 10.1016/s0022-5347(17)35130-3

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

Review 1.  Overactive bladder in children.

Authors:  Sophie Ramsay; Stéphane Bolduc
Journal:  Can Urol Assoc J       Date:  2017 Jan-Feb       Impact factor: 1.862

Review 2.  [Medical therapy of urinary incontinence].

Authors:  M Oelke; J J de la Rosette; M C Michel; U Jonas
Journal:  Internist (Berl)       Date:  2005-01       Impact factor: 0.743

Review 3.  Intravesical oxybutynin therapy for patients with neurogenic detrusor overactivity: a systematic review and meta-analysis.

Authors:  Si-Hong Shen; Xue Jia; Liao Peng; Xiao Zeng; Hong Shen; De-Yi Luo
Journal:  Int Urol Nephrol       Date:  2022-02-28       Impact factor: 2.370

Review 4.  [Overactive bladder--treatment with antimuscarinic agents].

Authors:  K Höfner
Journal:  Urologe A       Date:  2003-05-20       Impact factor: 0.639

Review 5.  Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability.

Authors:  Y E Yarker; K L Goa; A Fitton
Journal:  Drugs Aging       Date:  1995-03       Impact factor: 3.923

Review 6.  Intravesical therapy for overactive bladder.

Authors:  Robert J Evans
Journal:  Curr Urol Rep       Date:  2005-11       Impact factor: 2.862

7.  Long-Term Efficacy, Safety, and Tolerability of Modified Intravesical Oxybutynin Chloride for Neurogenic Bladder in Children.

Authors:  Masashi Honda; Yusuke Kimura; Panagiota Tsounapi; Katsuya Hikita; Motoaki Saito; Atsushi Takenaka
Journal:  J Clin Med Res       Date:  2019-03-18

Review 8.  Clinical utility of transdermal delivery of oxybutynin gel via a metered-dose pump in the management of overactive bladder.

Authors:  Adrian Wagg
Journal:  Res Rep Urol       Date:  2012-11-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.